Cancers, Vol. 10, Pages 115: YAP/TAZ Activation as a Target for Treating Metastatic Cancer

Cancers, Vol. 10, Pages 115: YAP/TAZ Activation as a Target for Treating Metastatic Cancer

Cancers doi: 10.3390/cancers10040115

Authors: Janine Warren Yuxuan Xiao John Lamar

Yes-Associated Protein (YAP) and Transcriptional Co-activator with PDZ-binding Motif (TAZ) have both emerged as important drivers of cancer progression and metastasis. YAP and TAZ are often upregulated or nuclear localized in aggressive human cancers. There is abundant experimental evidence demonstrating that YAP or TAZ activation promotes cancer formation, tumor progression, and metastasis. In this review we summarize the evidence linking YAP/TAZ activation to metastasis, and discuss the roles of YAP and TAZ during each step of the metastatic cascade. Collectively, this evidence strongly suggests that inappropriate YAP or TAZ activity plays a causal role in cancer, and that targeting aberrant YAP/TAZ activation is a promising strategy for the treatment of metastatic disease. To this end, we also discuss several potential strategies for inhibiting YAP/TAZ activation in cancer and the challenges each strategy poses.

https://ift.tt/2HnONED